trending Market Intelligence /marketintelligence/en/news-insights/trending/C7lTCGfshtH05B_p0h4kYw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Eli Lilly terminates insulin license agreement with Adocia

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Eli Lilly terminates insulin license agreement with Adocia

Eli Lilly & Co. backed out of an agreement to develop Adocia SA's ultra-rapid insulin BioChaperone Lispro.

BioChaperone Lispro is meant to treat people with both type 1 and type 2 diabetes. With the termination, the insulin's rights are reverted back to Adocia.

Adocia Chairman and CEO Gérard Soula said the company was "surprised" by Lilly's decision and would advance the insulin to phase 3 clinical trial with the help of a new partner.

Adocia had licensed the rights to the insulin in December 2014 in exchange for an up-front payment of $50 million. The company was also eligible to receive up to an additional $520 million in certain development, regulatory and sales milestones-related-payments.